Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-02-04T17:05:13.785Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotics and the risk of diabetes: A general data review

Published online by Cambridge University Press:  16 April 2020

T. Bottai ,
P. Quintin  and
E. Perrin
T. Bottai
Affiliation:
Service de psychiatrie générale de Martigues 13G24, hôpital du Vallon, BP 248, CH de Martigues, 13698Martigues cedex, France
P. Quintin*
Affiliation:
Lilly France, 13, rue Pages, 92158Suresnes cedex, France Hôpital Louis-Mourier, 178, rue des Renouillers, 92700Colombes, France
E. Perrin
Affiliation:
Lilly France, 13, rue Pages, 92158Suresnes cedex, France
*
*Corresponding author. E-mail address: quintin_philippe@lilly.com (P. Quintin).
Get access

Abstract

Recently, attention has focused on a potential link between schizophrenia and diabetes, with speculation that this potential associationis stronger in patients who are prescribed atypical antipsychotics. Pharmacoepidemiological studies can help to evaluate this potential association. Source data on the incidence of diabetes in patients treated with antipsychotics is available in the FDA MedWatch database, prescription claims databases and other patient registries. These data indicate that antipsychotic drugs may increase the risk of developing diabetes and that there may be an interaction with age. However, current data are insufficient to accurately assess potential differences in the risk of diabetes between users of individual antipsychotic medications. In addition, antipsychotic treatment-emergent diabetes has several distinct features, notably relating to age of onset, gender ratio, rate of deterioration of glycaemic control, and independence from initial treatment emergent weight gain. Nonetheless, guidelines for the control of risk factors for diabetes developed for the general population appear to be applicable to patients with schizophrenia.

Keywords

AntipsychoticsDiabetesData review
Type
Research Article
Information
European Psychiatry , Volume 20 , Issue S4 , December 2005 , pp. S349 - S357
Copyright
Copyright © European Psychiatric Association 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alberti K.G.M.N., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. 1999 http://whqlibdoc.who.int/hq/I999/WHO_NCD_NCS_99.2.pdf"Google Scholar
American Diabetes Association: clinical practice recommendations. Diabetes Care. 2000; 23 (Suppl 1): S1–S116Google Scholar
American Diabetes Association: clinical practice recommendations. Diabetes Care. 2002; 25Suppl 1: S1–S147Google Scholar
Beasley, C.M. JrTollefson, G.Tran, P.Satterlee, W.Sanger, T.Hamilton, S.Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1421996 111-23CrossRefGoogle ScholarPubMed
Beasley, C.M. JrSanger, T.Satterlee, W.Tollefson, G.Tran, P.Hamilton, S.Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996; 1241–2: 159–167CrossRefGoogle ScholarPubMed
Buse, J.B.Cavazzoni, P.Hornbuckle, K.Hutchins, D.Breier, A.Jovanovic, L.A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003; 56: 164–70CrossRefGoogle ScholarPubMed
Caro, J.J.Ward, A.Levinton, C.Robinson, K.The risk of diabetes during olanzapine use: a retrospective database analysis. J Clin Psychiatry. 2002; 63: 1135–39CrossRefGoogle ScholarPubMed
Cavazzoni P, Hornbuckle K, Carlson C, Wu J, Kotsanos J, Holman R,Diabetes mellitus and antipsychotic treatment in the United Kingdom. Poster NCDEU 2002 Section I-32. http://www.nimh.nih.gov/ncdeu/posterabstracts.cfmCrossRefGoogle Scholar
Cavazzoni, P.Mukhopadhyay, N.Carlson, C.Breier, A.Buse, J.Retrospective analysis of risk factors in patients with treatment emergent diabetes during clinical trial of antipsychotic medications. British Journal of Psychiatry. 2004; 184(Suppl 47): S94–S101.Corrigendum Br J Psychiatry Suppl. 2005 May; 186:449CrossRefGoogle Scholar
Charbonnel, B.Baigts, F.Dumenil, V.Paillasson, S.Baleydiet, A.Management of type 2 diabetic patients in France: any difference among physician? The Observational Epidemiologic SIMPA Study. Diabetologia. 2004; 47Suppl 1: A121Google Scholar
Dixon, L.Weiden, P.Delahanty, J.Goldberg, R.Postrado, L.Lucksted, A., et al.Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin. 2000; 26: 903–12CrossRefGoogle ScholarPubMed
Gianfrancesco, F.D.Grogg, A.L.Mahmoud, R.A.Wang, R.H.Nasrallah, H.A.Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plandatabase. J Clin Psychiatry. 2002; 63: 920–30CrossRefGoogle Scholar
Gianfrancesco, F.White, R.Wang, R.H.Nasrallah, H.A.Antipsychoticinduced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003; 23: 328–35CrossRefGoogle Scholar
Hedenmalm, K.Hagg, S.Stahl, M.Mortimer, O.Spigset, O.Glucose intolerance with atypical antipsychotics. Drug Saf. 2002; 25: 1107–16CrossRefGoogle ScholarPubMed
Jin, H.Meyer, J.M.Jeste, D.V.Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of5 published cases. Am Clin Psychiatry. 2002; 14: 59–64Google Scholar
Kaufman, F.R.Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab. 2002; 15(Suppl 2): 737-44CrossRefGoogle ScholarPubMed
Koller, E.A.Schneider, B.Bennett, K.Dubitsky, G.Clozapineassociated diabetes. Am J Med. 2001; 111: 716–23CrossRefGoogle ScholarPubMed
Koller, E.Doraiswamy, P.M.Olanzpine-associated diabetes mellitus. Pharmacotherapy. 2002; 22: 841–52CrossRefGoogle ScholarPubMed
Koller, E.A.Cross, J.T.Doraiswamy, P.M.Schneider, B.S.Risperidoneassociated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003; 23: 735–44CrossRefGoogle ScholarPubMed
Kornegay, C.J.Vasilakis-Scaramozza, C.Jick, H.Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002; 63: 758–62CrossRefGoogle ScholarPubMed
Koro, C.E.Fedder, D.O.L'Italien, G.J.Weiss, S.S.Magder, L.S.Kreyenbuhl, J., et al.Assessment of independent effect of olanzapine and risperidone on risk of diabetes: population based nested casecontrol study. BMJ. 2002; 325: 243–7CrossRefGoogle Scholar
Lage, M.J.Kemner, J.E.Use of atypical antipsychotics and the incidence of diabetes: evidence from a claims database. Schizophrenia Research. 2002; 53: 166Google Scholar
Lindenmayer, J.-P.Czobor, P.Volavka, J.Citrome, L.Sheitman, B.McEvoy, J.P., et al.Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003; 160: 290–6CrossRefGoogle ScholarPubMed
Mokdad, A.H.Ford, E.S.Bowman, B.A.Nelson, D.E.Engelgau, M.M.Vinicor, F., et al.Diabetes trends in the United States, 1990–1998. Diabetes Care. 2000; 23: 1278–83CrossRefGoogle ScholarPubMed
Mukherjee, S.Decina, P.Bocola, V.Saraceni, F.Scapicchio, P.Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry. 1996; 37: 68–73CrossRefGoogle ScholarPubMed
Regenold, W.T.Thapar, R.K.Marano, C.Gavirneni, S.Kondapavuluru, P.V.Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent ofpsychotropic drug use. J Affect Disord. 2002; 70: 19–26CrossRefGoogle Scholar
Rolka, D.B.Narayan, K.M.Thompson, T.J.Goldman, D.Lindenmayer, J.Alich, K., et al.Performance of recommended screening tests for undiagnosed diabetes and dysglycaemia. Diabetes Care. 2001; 24: 1899–903CrossRefGoogle Scholar
Ryan, M.C.M.Thakore, J.H.Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002; 71: 239–57CrossRefGoogle ScholarPubMed
Sernyak, M.J.Leslie, D.L.Alarcon, R.D.Losonczy, M.F.Rosenheck, R.Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002; 159: 561–6CrossRefGoogle ScholarPubMed
Shermock, K.M.Fuller, M.A.Secic, M.Grogg, A.The relationship between antipsychotics and the development of diabetes in a VA population. Int J Neuropsychopharmacol. 2002; 5Suppl 1: S168Google Scholar
Smith, R.C.Lindenmayer, J.P.Khan, M.Khandot, A.Bodala, P.A prospective cross-sectional of glucose and lipid metabolism with atypical and conventional antipsychotics. Biological Psychiatry. 2002; 51: S42Google Scholar
Stang, P.E.Fox, J.L.Adverse drug events and the freedom of information act: an apple in Eden. Ann Pharmacother. 1992; 26: 238–43CrossRefGoogle ScholarPubMed
Tollefson, G.D.Beasley, C.M. JrTran, P.V.Street, J.S.Krueger, J.A.Tamura, R.N., et al.Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an internationalcollaborative trial. Am J Psychiatry 15441997 457-65Google ScholarPubMed
Tollefson, G.D.Dellva, M.A.Mattler, C.A.Kane, J.M.Wirshing, D.A.Kinon, B.J.Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The CollaborativeCrossover Study Group. J Clin Psychopharmacol 1951999 435-43CrossRefGoogle ScholarPubMed
Tollefson, G.D.Birkett, M.A.Kiesler, G.M.Wood, A.J.Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible fortreatment with clozapine. Biol Psychiatry. 2001; 491: 52–63CrossRefGoogle Scholar
Tran, P.V.Hamilton, S.H.Kuntz, A.J.Potvin, J.H.Andersen, S.W.Beasley, C. Jr, et al.Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 175: 407-18CrossRefGoogle ScholarPubMed
Wirshing, D.A.Boyd, J.A.Meng, L.R.Ballon, J.S.Marder, S.R.Wirshing, W.C.The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002; 63: 856–65CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.